Figure 6.

Chronic administration of BAY 60-4552, but not GSK2181236A attenuated the increase in (A) urine output, (B) microalbumin excretion, and (C) sodium excretion in age-matched HSFD SHR-SPs. Neither compound altered glomerular filtration rate as estimated by (D) creatinine clearance. Treatments were administered in chow starting 1 week after the initiation of HSFD. Data for moribund animals or animals that died prior to the end of study were not included. Remaining data were analyzed using two-way ANOVA analysis with a Bonferroni’s post-test and statistical comparisons were made to the HSFD control (*P < 0.05 and ***P < 0.001; data are presented as mean ± SEM of three to nine animals per group).